BioNeutra Global Corporation BGACF
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -4.47% | -15.03% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.47% | -15.03% | -- | -- | -- |
| Cost of Revenue | -38.90% | -48.71% | -- | -- | -- |
| Gross Profit | 285.33% | 303.10% | -- | -- | -- |
| SG&A Expenses | 3.84% | 3.39% | -- | -- | -- |
| Depreciation & Amortization | -19.95% | -13.13% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.95% | -31.85% | -- | -- | -- |
| Operating Income | 80.68% | 79.52% | -- | -- | -- |
| Income Before Tax | 87.12% | 66.76% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 87.12% | 66.76% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.12% | 66.76% | -- | -- | -- |
| EBIT | 80.68% | 79.52% | -- | -- | -- |
| EBITDA | 99.34% | 103.97% | -- | -- | -- |
| EPS Basic | 87.63% | 67.34% | -- | -- | -- |
| Normalized Basic EPS | 67.18% | 68.68% | -- | -- | -- |
| EPS Diluted | 72.68% | 53.85% | -- | -- | -- |
| Normalized Diluted EPS | 67.18% | 68.68% | -- | -- | -- |
| Average Basic Shares Outstanding | -0.40% | -0.40% | -- | -- | -- |
| Average Diluted Shares Outstanding | -0.40% | -0.40% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |